Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [142]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Research works printed but not linked: 3
- D. Pardoll, Nature411, 1010 (2001).
- Y. Naito et al., Cancer Res.58, 3491 (1998).
- We thank A. Rodi and M. Pelegrin for expert technical assistance; I. Gresser for helpful comments and critical review of the manuscript; and D. Frucht C. Anderson and T. Pokrovska for critically reading the manuscript. Supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA) INSERM Action Concertée Incitative ACI IMPBio Université Paris-Descartes Paris 5 and the Austrian Federal Ministry of Education Science and Culture (GBN-AU project Bioinformatics Integration Network).
Cited by
Items 1,001–1,043 of 1,043
Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115
Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113
Colon cancer cells produce immunoregulatory glucocorticoids
Sidler, D., Renzulli, P., Schnoz, C., Berger, B., Schneider-Jakob, S., Flück, C., Inderbitzin, D., Corazza, N., Candinas, D., & Brunner, T. (2011) · Oncogene · doi:10.1038/onc.2010.629 · Cited by 107
“In line with this notion are recent findings demonstrating that the degree of tumor infiltration by memory CD8þ T cells strongly correlates with the overall survival of CRC patients (Pages et al., 2005; Galon et al., 2006), indicating that anti-tumor immune responses are able to significantly limit tumor growth.”
End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study
Jiang, X., Hoffmeister, M., Brenner, H., Muti, H. S., Yuan, T., Foersch, S., West, N. P., Brobeil, A., Jonnagaddala, J., Hawkins, N., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00208-x · Cited by 108
Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107
Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01120-y · Cited by 106
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
BackgroundShia, J., Schultz, N., Kuk, D., Vakiani, E., Middha, S., Segal, N. H., Hechtman, J. F., Berger, M. F., Stadler, Z. K., Weiser, M. R., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.198 · Cited by 105
Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2605 · Cited by 103
Nicheformer: a foundation model for single-cell and spatial omics
Tejada-Lapuerta, A., Schaar, A. C., Gutgesell, R., Palla, G., Halle, L., Minaeva, M., Vornholz, L., Dony, L., Drummer, F., Richter, T., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02814-z · Cited by 100
Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
Fakih, M., Ouyang, C., Wang, C., Tu, T. Y., Gozo, M. C., Cho, M., Sy, M., Longmate, J. A., & Lee, P. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127046 · Cited by 84
Yang, Y., Attwood, K., Bshara, W., Mohler, J. L., Guru, K., Xu, B., Kalinski, P., & Chatta, G. (2021) · The Prostate · doi:10.1002/pros.24068 · Cited by 88
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013474 · Cited by 85
“Moreover, in colorectal cancer the presence of T cells in tumors correlates with survival of patients [50].”
BackgroundPD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Williams, D. S., Mouradov, D., Jorissen, R. N., Newman, M. R., Amini, E., Nickless, D. K., Teague, J. A., Fang, C. G., Palmieri, M., Parsons, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315664 · Cited by 79
Lutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P. A., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7c70 · Cited by 77
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
TGFβ and cancer metastasis: an inflammation link
Yang, L. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9226-3 · Cited by 65
“carcinoma [85] and colorectal tumors [86], as well as breast cancer [87].”
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
“It better correlated to prognosis in localized tumors than to the T and N stages [60].”
BackgroundJamieson, N. B., Mohamed, M., Oien, K. A., Foulis, A. K., Dickson, E. J., Imrie, C. W., Carter, C. R., McKay, C. J., & McMillan, D. C. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2370-y · Cited by 60
Koti, M., Siu, A., Clément, I., Bidarimath, M., Turashvili, G., Edwards, A., Rahimi, K., Masson, A.-M. M., & Squire, J. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.81 · Cited by 57
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
“A high density of cytotoxic T lymphocytes in CRCs are associated with better relapse-free and overall survival [101–103].”
BackgroundCarmona-Rodríguez, L., Martínez-Rey, D., Fernández-Aceñero, M. J., González-Martín, A., Paz-Cabezas, M., Rodríguez-Rodríguez, N., Pérez-Villamil, B., Sáez, M. E., Díaz-Rubio, E., Mira, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000432 · Cited by 51
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Ni, K., Zhao, L., Wu, J., Chen, W., HongyaYang, & Li, X. (2015) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2015.06.026 · Cited by 46
Bodduluri, S. R., Mathis, S., Maturu, P., Krishnan, E., Satpathy, S. R., Chilton, P. M., Mitchell, T. C., Lira, S., Locati, M., Mantovani, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0424 · Cited by 45
Fantini, M. C., Favale, A., Onali, S., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186744 · Cited by 40
“Since high density of cytotoxic CD8+ and IFNγ CD3+ T cells at the invasive margin is associated with better outcomes [90], the local accumulation of Tregs at this site might dampen the anti-tumor activity.”
BackgroundMorris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0194 · Cited by 38
Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900017 · Cited by 36
Bo, H., Zhu, F., Liu, Z., Deng, Q., Liu, G., Li, R., Zhu, W., Tan, Y., Liu, G., Fan, J., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00588-9 · Cited by 35
“In the tumor microenvironment, immune cells and stromal cells are the two main types of non-tumor components that have potential value for the clinical diagnosis and prognostic evaluation of tumors [14].”
BackgroundRapoport, B. L., Nayler, S., Mlecnik, B., Smit, T., Heyman, L., Bouquet, I., Martel, M., Galon, J., Benn, C.-A., & Anderson, R. (2022) · Cancers · doi:10.3390/cancers14102525 · Cited by 33
Self-citationShaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells
Humbert, M., Hugues, S., & Dubrot, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00684 · Cited by 32
“While cytotoxic T lymphocyte infiltration correlates with good prognosis, accumulation of T regulatory cells (Treg) or naïve T cells is detrimental for the clinical outcome (59, 60).”
BackgroundHaasnoot, K. J. C., Backes, Y., Moons, L. M. G., Kranenburg, O., Trinh, A., Vermeulen, L., Noë, M., Tuynman, J. B., van Lent, A. U. G., van Ginneken, R., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0598-9 · Cited by 30
Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., et al. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00601-7 · Cited by 29
Grange, C., Létourneau, J., Forget, M.-A., Godin-Ethier, J., Martin, J., Liberman, M., Latour, M., Widmer, H., Lattouf, J.-B., Piccirillo, C. A., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.002 · Cited by 29
Yanai, Y., Kosaka, T., Mikami, S., Hongo, H., Yasumizu, Y., Takeda, T., Matsumoto, K., Miyauchi, J., Kitano, S., & Oya, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-01900-4 · Cited by 28
Plattner, C., Lamberti, G., Blattmann, P., Kirchmair, A., Rieder, D., Loncova, Z., Sturm, G., Scheidl, S., Ijsselsteijn, M., Fotakis, G., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108399 · Cited by 27
Self-citationBissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08702-x · Cited by 24
Malczewski, A. B., Ketheesan, N., Coward, J. I. G., & Navarro, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624434 · Cited by 22
Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., et al. (2023) · Cells · doi:10.3390/cells12010180 · Cited by 20
“Among these noncancer cells in the TME, tumor-infiltrating immune cells (TIICs) play a central role in predicting the metastasis and mortality of various tumors [12].”
Backgroundvan Rijthoven, M., Balkenhol, M., Siliņa, K., van der Laak, J., & Ciompi, F. (2021) · Medical Image Analysis · doi:10.1016/j.media.2020.101890 · Cited by 16
Expression of the immune checkpoint receptor TIGIT in seminoma
Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10428 · Cited by 12
Metadata
- Authors
- Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Pagès, F.
- Affiliations
- INSERM U 255, Paris, 75006 France; Université Paris-Descartes Paris 5, Faculté de Médecine, Paris, 75006 France; and Université Pierre et Marie Curie Paris 6, Institut des Cordeliers, Paris, 75006 France.
- Inserm (FR)
- ORCID
- Venue
- Science
- Published
- 2006-09-29
- Volume
- 313
- Issue
- 5795
- Pages
- 1960-1964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2142300779
- Cited by
- 6,516
- References
- 31
- Citations by year
- 2026: 237 · 2025: 278 · 2024: 329 · 2023: 444 · 2022: 451 · 2021: 574 · 2020: 524 · 2019: 433 · 2018: 447 · 2017: 405 · 2016: 394 · 2015: 380 · 2014: 268 · 2013: 282 · 2012: 237
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, tumor-infiltrating immune cells, adaptive immune response, prognostic factors, patient survival, tumor immune microenvironment, gene expression profiling, cancer immunotherapy
- MeSH terms
- Female, Humans, Immunohistochemistry, Immunologic Memory, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Cohort Studies, Survival Analysis, Polymerase Chain Reaction, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD3 Complex, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Th1 Cells, Disease Progression, Disease-Free Survival, Lymphocyte Count, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.